Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease

Cytokine and Growth Factor Reviews

Volumn 22, Issue 4, 2011, Pages 177-187

  Decker, William K ^a   Safdar, Amar ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvantation; Cytokines; Historical perspective; Immunotherapy; Therapeutic vaccination

Indexed keywords

ADJUVANT; ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMATINIB; IMIQUIMOD; INFLUENZA A ANTIGEN; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; LA CROSSE ANTIGEN; MELACINE; MELAN A; OMEGA INTERFERON; PEPTIDE VACCINE; POXVIRUS VACCINE; RECOMBINANT ALPHA2B INTERFERON; RESIQUIMOD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS ANTIGEN; VIRUS VACCINE; VITESPEN;

BASAL CELL CARCINOMA; BREAST TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; GLIOMA; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; IMMUNOPROPHYLAXIS; INFECTION; MELANOMA; MYELOMA; NONHUMAN; NOTE; OVARY TUMOR; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE TUMOR; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CANCER VACCINES; CYTOKINES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VACCINATION; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS;

EID: 81155133847     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.07.001     Document Type: Note

References (131)

1. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298(November 14 (18)):2155-2163.
2. Lombard M., Pastoret P.P., Moulin A.M. A brief history of vaccines and vaccination. Rev Sci Tech 2007, 26(April (1)):29-48.
3. Hopkins D.R. Princes and peasants: smallpox in history 1983, University of Chicago Press, Chicago.
4. Atkinson W., Hamborsky J., McIntyre L., Wolfe S. Epidemiology and prevention of vaccine-preventable diseases 2005, Public Health Foundation, Washington, DC. 9th ed.
5. Hopkins D.R. The greatest killer: smallpox in history 2002, University of Chicago Press, Chicago.
6. Porter J.R. Agostino Bassi bicentennial (1773-1973). Bacteriol Rev 1973, 37(September (3)):284-288.
7. Ullmann A. Pasteur-Koch: distinctive ways of thinking about infectious diseases. Microbe 2007, 2(8):383-387.
8. Herr H.W. Ignorance is bliss: the Listerian revolution and education of American surgeons. J Urol 2007, 177(February (2)):457-460.
9. Gradmann C. A matter of methods: the historicity of Koch's postulates 1840-2000. Medizinhist J 2008, 43(2):121-148.
10. Mandell G.L., Bennett J.E., Dolin R. Principles and practice of infectious diseases 2004, Churchill Livngstone, New York. 6th ed.
11. Beasley R.P. Development of hepatitis B vaccine. JAMA 2009, 302(July 15 (3)):322-324.
12. Parish C.R. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol 2003, 81(April (2)):106-113.
13. Decker W.K., Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev 2009, 20(August (4)):271-281.
14. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004, 5(December (12)):1219-1226.
15. Decker W.K., Xing D., Shpall E.J. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant 2006, 12(February (2)):113-125.
16. Guiducci C., Ott G., Chan J.H., et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006, 203(August 7 (8)):1999-2008.
17. McKenna K., Beignon A.S., Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 2005, 79(January (1)):17-27.
18. Piccioli D., Sammicheli C., Tavarini S., et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 2009, 113(April 30 (18)):4232-4239.
19. Barnes E., Salio M., Cerundolo V., et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 2004, 48(September (9)):3382-3389.
20. Schmidt J., Patrut E.M., Ma J., et al. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 2006, 55(November (11)):1396-1405.
21. Schmidt J., Jager D., Hoffmann K., Buchler M.W., Marten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 2007, 30(January (1)):108-115.
22. Hendil K.B., Khan S., Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J 1998, 332(June 15 (Pt 3)):749-754.
23. Tosello V., Zamarchi R., Merlo A., et al. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol 2009, 39(January (1)):56-66.
24. Di P.T., Pilla L., Capone I., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006, 66(May 1 (9)):4943-4951.
25. Pilla L., Patuzzo R., Rivoltini L., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006, 55(August (8)):958-968.
26. Bocchia M., Gentili S., Abruzzese E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365(February 19 (9460)):657-662.
27. Vaishampayan U., Abrams J., Darrah D., Jones V., Mitchell M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002, 8(December (12)):3696-3701.
28. Hance K.W., Rogers C.J., Zaharoff D.A., Canter D., Schlom J., Greiner J.W. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res 2009, 15(April 1 (7)):2387-2396.
29. Hodge J.W., Sabzevari H., Yafal A.G., Gritz L., Lorenz M.G., Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999, 59(November 15 (22)):5800-5807.
30. Lousberg E.L., Diener K.R., Fraser C.K., et al. Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition. J Virol 2011, 85(April (7)):3385-3396.
31. Marshall J.L., Gulley J.L., Arlen P.M., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23(February 1 (4)):720-731.
32. Kaufman H.L., Kim-Schulze S., Manson K., et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007, 5:60.
33. Gallagher K.M., Lauder S., Rees I.W., Gallimore A.M., Godkin A.J. Type I interferon (IFN alpha) acts directly on human memory CD4+T cells altering their response to antigen. J Immunol 2009, 183(September 1 (5)):2915-2920.
34. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 2008, 26(September 15 (39)):4998-5003.
35. Couch R.B., Atmar R.L., Cate T.R., et al. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 2009, 27(August 27 (39)):5344-5348.
36. O'Brien L., Perkins S., Williams A., et al. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J Gen Virol 2009, 90(April (4)):874-882.
37. Miquilena-Colina M.E., Lozano-Rodriguez T., Garcia-Pozo L., et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 2009, 27(September 18 (41)):5654-5660.
38. Mazzoni A., Leifer C.A., Mullen G.E., Kennedy M.N., Klinman D.M., Segal D.M. Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells. J Immunol 2003, 170(March 1 (5)):2269-2273.
39. Zhang W., Du X., Zhao G., et al. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine 2009, 27(August 6 (36)):4938-4946.
40. Honda K., Ohba Y., Yanai H., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434(April 21 (7036)):1035-1040.
41. Honda K., Yanai H., Negishi H., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(April 7 (7034)):772-777.
42. Jung J., Yi A.K., Zhang X., Choe J., Li L., Choi Y.S. Distinct response of human B cell subpopulations in recognition of an innate immune signal CpG DNA. J Immunol 2002, 169(September 1 (5)):2368-2373.
43. Murad Y.M., Clay T.M. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 2009, 23(6):361-375.
44. Rynkiewicz D., Rathkopf M., Sim I., et al. Marked enhancement of the immune response to BioThrax((R)) (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 2011, (May 30).
45. Crompton P.D., Mircetic M., Weiss G., et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 2009, 182(March 1 (5)):3318-3326.
46. Ellis R.D., Martin L.B., Shaffer D., et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010, 5(1):e8787.
47. Cooper C.L., Davis H.L., Morris M.L., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22(August 13 (23-24)):3136-3143.
48. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46(April 15 (8)):1310-1314.
49. Sogaard O.S., Lohse N., Harboe Z.B., et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51(July 1 (1)):42-50.
50. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8+T cell responses to vaccination with peptide IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115(March (3)):739-746.
51. Speiser D.E., Schwarz K., Baumgaertner P., et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010, 33(October (8)):848-858.
52. Valmori D., Souleimanian N.E., Tosello V., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007, 104(May 22 (21)):8947-8952.
53. Shukla N.M., Malladi S.S., Mutz C.A., Balakrishna R., David S.A. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. J Med Chem 2010, 53(June 10 (11)):4450-4465.
54. Rajagopal D., Paturel C., Morel Y., Uematsu S., Akira S., Diebold S.S. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115(March 11 (10)):1949-1957.
55. Tarhini A.A., Agarwala S.S. First international symposium on melanoma and other cutaneous malignancies. Expert Opin Biol Ther 2004, 4(September (9)):1541-1546.
56. Adams S., O'Neill D.W., Nonaka D., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181(July 1 (1)):776-784.
57. Daayana S., Elkord E., Winters U., et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010, 102(March 30 (7)):1129-1136.
58. Morse M.A., Bradley D.A., Keler T., et al. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines 2011, 10(June (6)):733-742.
59. Drexler H.G., Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004, 22(June (2)):71-73.
60. Lyman S.D., Jacobsen S.E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91(February 15 (4)):1101-1134.
61. Maraskovsky E., Brasel K., Teepe M., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996, 184(November 1 (5)):1953-1962.
62. Onai N., Obata-Onai A., Schmid M.A., Manz M.G. Flt3 in regulation of type I interferon-producing cell and dendritic cell development. Ann N Y Acad Sci 2007, 1106(June):253-261.
63. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3(September (9)):650-665.
64. Disis M.L., Rinn K., Knutson K.L., et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002, 99(April 15 (8)):2845-2850.
65. McNeel D.G., Knutson K.L., Schiffman K., Davis D.R., Caron D., Disis M.L. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003, 23(January (1)):62-72.
66. Shackleton M., Davis I.D., Hopkins W., et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004, 4(September 23):9.
67. Pulendran B., Smith J.L., Jenkins M., Schoenborn M., Maraskovsky E., Maliszewski C.R. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med 1998, 188(December 7 (11)):2075-2082.
68. Teleshova N., Jones J., Kenney J., et al. Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells. J Leukoc Biol 2004, 75(June (6)):1102-1110.
69. Triccas J.A., Shklovskaya E., Spratt J., et al. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect Immun 2007, 75(November (11)):5368-5375.
70. Xu J., Xu W., Chen X., Zhao D., Wang Y. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine 2008, 26(August 18 (35)):4519-4525.
71. Encke J., Bernardin J., Geib J., Barbakadze G., Bujdoso R., Stremmel W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J Gastroenterol 2006, 12(November 28 (44)):7118-7125.
72. Zhang T., Hashizume T., Kurita-Ochiai T., Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem Biophys Res Commun 2009, 390(December 18 (3)):937-941.
73. Decker W.K., Xing D., Li S., et al. Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. Blood 2009, 113(April 30 (18)):4213-4223.
74. Del V.M., Bajetta E., Canova S., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13(August 15 (16)):4677-4685.
75. Langrish C.L., McKenzie B.S., Wilson N.J., de Waal M.R., Kastelein R.A., Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, December (202):96-105.
76. Hansson L., Abdalla A.O., Moshfegh A., et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007, 13(March 1 (5)):1503-1510.
77. Hamid O., Solomon J.C., Scotland R., et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007, 13(January 1 (1)):215-222.
78. Kikuchi T., Akasaki Y., Abe T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004, 27(November (6)):452-459.
79. Cebon J., Jager E., Shackleton M.J., et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003, 3(July 16 (7)).
80. Peterson A.C., Harlin H., Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003, 21(June 15 (12)):2342-2348.
81. Lee P., Wang F., Kuniyoshi J., et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001, 19(September 15 (18)):3836-3847.
82. Gajewski T.F., Fallarino F., Ashikari A., Sherman M. Immunization of HLA-A2+melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001, 7(March (3 Suppl)):895s-901s.
83. O'Toole M., Wooters J., Brown E., et al. Interleukin-12 as adjuvant in peptide vaccines. Ann N Y Acad Sci 1996, 795(October 31):379-381.
84. Operschall E., Schuh T., Heinzerling L., Pavlovic J., Moelling K. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. J Clin Virol 1999, 13(June (1-2)):17-27.
85. Parker J.N., Pfister L.A., Quenelle D., et al. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine 2006, 24(March 6 (10)):1644-1652.
86. Arulanandam B.P., O'Toole M., Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 1999, 180(October (4)):940-949.
87. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 2000, 164(April 1 (7)):3698-3704.
88. Williman J., Lockhart E., Slobbe L., Buchan G., Baird M. The use of Th1 cytokines IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine 2006, 24(May 22 (21)):4471-4474.
89. Galarza J.M., Latham T., Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005, 18(1):244-251.
90. Chattergoon M.A., Saulino V., Shames J.P., Stein J., Montaner L.J., Weiner D.B. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 2004, 22(April 16 (13-14)):1744-1750.
91. Hwang S.A., Wilk K.M., Budnicka M., et al. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine 2007, 25(September 17 (37-38)):6730-6743.
92. Gazitt Y., Shaughnessy P., Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001, 10(February (1)):177-186.
93. Robin G., Markovich S., Athamna A., Keisari Y. Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 1991, 10(August (4)):257-263.
94. Schuster S.J., Venugopal P., Kern J.C., McLaughlin P. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma 2008, 49(September (9)):1681-1692.
95. Shaughnessy P.J., Bachier C., Lemaistre C.F., Akay C., Pollock B.H., Gazitt Y. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. Stem Cells 2006, 24(July (7)):1789-1797.
96. Steis R.G., VanderMolen L.A., Longo D.L., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst 1990, 82(April 18 (8)):697-703.
97. Young D.A., Lowe L.D., Clark S.C. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990, 145(July 15 (2)):607-615.
98. Charak B.S., Agah R., Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993, 81(June 15 (12)):3474-3479.
99. Connor R.I., Shen L., Fanger M.W. Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. J Immunol 1990, 145(September 1 (5)):1483-1489.
100. Keler T., Wallace P.K., Vitale L.A., et al. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol 2000, 164(June 1 (11)):5746-5752.
101. Samanci A., Yi Q., Fagerberg J., et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998, 47(November (3)):131-142.
102. Leong S.P., Enders-Zohr P., Zhou Y.M., et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999, 22(March (2)):166-174.
103. Simmons S.J., Tjoa B.A., Rogers M., et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999, 39(June 1 (4)):291-297.
104. von M.M., Arlen P., Gulley J., et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001, 7(May (5)):1181-1191.
105. Somani J., Lonial S., Rosenthal H., Resnick S., Kakhniashvili I., Waller E.K. A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. Vaccine 2002, 21(December 13 (3-4)):221-230.
106. Weber J., Sondak V.K., Scotland R., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003, 97(January 1 (1)):186-200.
107. Scheibenbogen C., Schadendorf D., Bechrakis N.E., et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003, 104(March 20 (2)):188-194.
108. Dillman R.O., Wiemann M., Nayak S.K., DeLeon C., Hood K., DePriest C. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother 2003, 26(July (4)):367-373.
109. Ullenhag G.J., Frodin J.E., Jeddi-Tehrani M., et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004, 10(May 15 (10)):3273-3281.
110. Neidhart J., Allen K.O., Barlow D.L., et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 2004, 22(January 26 (5-6)):773-780.
111. Barrio M.M., de Motta P.T., Kaplan J., et al. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 2006, 29(July (4)):444-454.
112. Safdar A., Rodriguez G.H., Rueda A.M., et al. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 2008, 113(July 15 (2)):383-387.
113. Yagci M., Acar K., Sucak G.T., Yamac K., Haznedar R. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. Eur J Haematol 2007, 79(October (4)):292-296.
114. Overton E.T., Kang M., Peters M.G., et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010, 28(August 2 (34)):5597-5604.
115. Spearman P., Kalams S., Elizaga M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27(January 7 (2)):243-249.
116. Ryan A.A., Wozniak T.M., Shklovskaya E., et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 2007, 179(December 15 (12)):8418-8424.
117. Dou J., Tang Q., Yu F., et al. Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb/c mice model. Immunobiology 2010, 215(2):133-142.
118. Nambiar J.K., Ryan A.A., Kong C.U., Britton W.J., Triccas J.A. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol 2010, 40(January (1)):153-161.
119. McCormick S., Santosuosso M., Zhang X.Z., Xing Z. Manipulation of dendritic cells for host defence against intracellular infections. Biochem Soc Trans 2006, 34(April (Pt 2)):283-286.
120. Zhang L., Yang Y., Yang X., et al. T cell epitope-based peptide-DNA dual vaccine induces protective immunity against Schistosoma japonicum infection in C57BL/6J mice. Microbes Infect 2008, 10(March (3)):251-259.
121. Gupta S., Garg N.J. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 2010, 4(8):e797.
122. Li X., Fujio M., Imamura M., et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 2010, 107(July 20 (29)):13010-13015.
123. Kopecky-Bromberg S.A., Fraser K.A., Pica N., et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 2009, 27(June 8 (28)):3766-3774.
124. Courtney A.N., Nehete P.N., Nehete B.P., Thapa P., Zhou D., Sastry K.J. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 2009, 27(May 26 (25-26)):3335-3341.
125. Thapa P., Zhang G., Xia C., et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009, 27(May 26 (25-26)):3484-3488.
126. Zhang R., Zhang S., Li M., Chen C., Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010, 28(July 12 (31)):5114-5127.
127. Hanks B.A., Jiang J., Singh R.A., et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005, 11(February (2)):130-137.
128. Sonpavde G., Slawin K.M., Spencer D.M., Levitt J.M. Emerging vaccine therapy approaches for prostate cancer. Rev Urol 2010, 12(1):25-34.
129. Cote P.J., Butler S.D., George A.L., et al. Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. J Med Virol 2009, 81(October (10)):1760-1772.
130. Brignone C., Grygar C., Marcu M., Perrin G., Triebel F. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 2007, 11-25(June (24)):4641-4650.
131. Morrow M.P., Pankhong P., Laddy D.J., et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009, 113(June 4 (23)):5868-5877.